Oncolytics Biotech Inc.

NASDAQ:ONCY

Biotechnology

Healthcare
$0.50 +3.03%

+$0.03 today

Market cap
$50.41M
Beta
1.08
P/E (TTM)
-4.3
EPS (TTM)
-$0.32
52W Low $0.56High $1.51

Volume 0.38M

Average 1.26M

ONCY Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Oncolytics Biotech Inc.NASDAQ: ONCY

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue growth accelerates

Q1 FY2026 cost of revenue of CA$22.31K rose 17.4% year over year, ahead of the -26.6% change in trailing-twelve-month cost of revenue. Over 3 fiscal years it compounded at -38.5% a year.

Context

  • Cost of revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +17.4% holds above the trailing-twelve-month pace of -26.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$22.31K— QoQ
Last fiscal yearDec 2025
CA$70K-19.5% YoY
LTMMar 2026
CA$119.31K-26.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.4%——
1 year-19.5%——
3-year CAGR-38.5%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

CAD · from the income statement

Latest · FY2025
70K CAD
Year-over-year change
-19.5%
4-year CAGR
-33.6%

Cost of Revenue vs competitors

How ONCY compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -26.6% is the 3rd highest of 7, against a peer median of -90.0%.
  • Over three fiscal years its annual growth of -38.5% compares with a peer median of -50.3%.
ONCY Competitors
Cost of Revenue for ONCY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGNXMacroGenics, Inc.LTM Mar 2026$47.23M USD-18.4%+80.2%30.1%
CLNNClene Inc.LTM Mar 2026$378K USD+410.8%+18.3%282.1%
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$151K USD———
IMMXImmix Biopharma, Inc.LTM Mar 2026$130.77K USD———
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$119.31K CAD-26.6%-38.5%—
SRZNSurrozen, Inc.LTM Mar 2026$65K USD-83.2%-45.2%0.9%
TILInstil Bio, Inc.LTM Mar 2026$24K USD-96.8%-55.3%—
COYACoya Therapeutics, Inc.LTM Mar 2026$16.49K USD-99.9%-81.6%0.2%
WHWKWhitehawk Therapeutics IncLTM Mar 2026$5K USD-100.0%-71.8%—
Peer median (excluding ONCY) —-90.0%-50.3%15.5%

Competitors are the stored peer set for ONCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue360.58K301.11K298.59K87K70K
Gross Profit(360.58K)(301.11K)(298.59K)(87K)(70K)
Gross Margin—————
Research & Development10.31M11.85M13.12M21.65M18.27M
Selling, General & Admin10.26M8.53M11.62M13.34M21.15M
Operating Expenses20.56M20.38M24.74M34.98M39.41M
Depreciation & Amortization360.58K301.11K298.59K102K96.05K
EBITDA(20.58M)(18.71M)(20.19M)(34.88M)(39.41M)
EBITDA Margin—————
Operating Income(20.93M)(20.68M)(25.04M)(34.98M)(39.41M)
Operating Margin—————
Interest Income99K528K1.33M1.2M529.64K
Interest Expense00000
Other Income / Expenses(15.88K)1.67M4.55M3.4M61.75K
Income Before Tax(20.94M)(19.01M)(20.49M)(31.58M)(39.35M)
Pre-Tax Margin—————
Income Tax Expense39.42K64.52K71.87K130K108.4K
Net Income(20.98M)(19.08M)(20.56M)(31.71M)(39.46M)
Net Margin—————
EPS (Basic)(0.49)(0.44)(0.41)(0.41)(0.41)
EPS (Diluted)(0.49)(0.44)(0.41)(0.41)(0.41)
Weighted Avg Shares53.51M58.03M67.62M76.48M95.86M
Weighted Avg Shares (Diluted)53.51M58.03M67.62M76.48M95.86M

Oncolytics Biotech Inc.

NASDAQ:ONCY

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.